New Evidence on the Management of Spondyloarthritis

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2016 Apr 8

PMID 27052489

Citations 45

Authors

Joachim Sieper

Denis Poddubnyy

Affiliations

Soon will be listed here.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for patients with symptomatic axial spondyloarthritis (SpA), who seem to respond best if treated early in the course of disease. The effect of NSAIDs on radiographic disease progression is less clear. Conventional disease-modifying antirheumatic drugs (DMARDs) are not recommended in the treatment of axial SpA, either alone or in combination with TNF blockers. Patients with nonradiographic axial SpA (nr-axSpA) seem to respond as well to TNF blockers as do patients with radiographic axial SpA (ankylosing spondylitis (AS)). However, patients with nr-axSpA should, in addition to a high severity of symptoms, also have objective signs of inflammation, detectable by MRI or by C-reactive protein testing, to be treated with TNF blockers. Whether early TNF-blocker treatment can retard new bone formation needs clarification. In clinical trials, anti-IL-17 agents and TNF blockers showed similar efficacy in patients with AS. The potential of IL-23 blockade for treatment of axial SpA needs to be further investigated. Treatment options for peripheral SpA have been much less thoroughly investigated than those for axial SpA. However, some data indicate that TNF blockers are effective for treating peripheral arthritis, enthesitis and dactylitis, the typical manifestations of peripheral SpA.

Citing Articles

Characteristics and multi-omics analysis of spontaneous spondyloarthritis in non-human primates: Case report.

Cai L, Lv Q, Ma R, Liu W, Guan Y, Huang Z Heliyon. 2025; 11(2):e41706.

PMID: 39877611 PMC: 11773035. DOI: 10.1016/j.heliyon.2025.e41706.

Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs.

Al Mohamad F, Rios Rodriguez V, Haibel H, Protopopov M, Rademacher J, Sieper J RMD Open. 2024; 10(1).

PMID: 38360039 PMC: 10875534. DOI: 10.1136/rmdopen-2023-004009.

Programmed cell death 10 can be used as a potential biomarker for ankylosing spondylitis diagnosis and treatment.

Ni W, Leng X Spinal Cord. 2023; 62(3):99-103.

PMID: 38158408 DOI: 10.1038/s41393-023-00952-9.

Reiter's syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder carcinoma: Case report.

Alsulami H, Al-Nashiwaty O, Khalifa M, Syed N, Ahmed N, Almuthree S IDCases. 2023; 31:e01711.

PMID: 36911867 PMC: 9996374. DOI: 10.1016/j.idcr.2023.e01711.

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.

Paroli M, Caccavale R, Paroli M, Spadea L, Accapezzato D Int J Mol Sci. 2023; 24(2).

PMID: 36674537 PMC: 9866163. DOI: 10.3390/ijms24021027.

References

Paramarta J, De Rycke L, Heijda T, Ambarus C, Vos K, Dinant H . Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2012; 72(11):1793-9. DOI: 10.1136/annrheumdis-2012-202245. View

Papp K, Thaci D, Reich K, Riedl E, Langley R, Krueger J . Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015; 173(4):930-9. DOI: 10.1111/bjd.13932. View

Gordon K, Callis Duffin K, Bissonnette R, Prinz J, Wasfi Y, Li S . A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015; 373(2):136-44. DOI: 10.1056/NEJMoa1501646. View

Boersma J . Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol. 1976; 5(1):60-4. View

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P . Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; 373(26):2534-48. DOI: 10.1056/NEJMoa1505066. View

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E . 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70(6):896-904. PMC: 3086052. DOI: 10.1136/ard.2011.151027. View

Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J . Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2013; 73(1):243-6. DOI: 10.1136/annrheumdis-2012-203055. View

Braun J, Baraliakos X, Hermann K, Deodhar A, van der Heijde D, Inman R . The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2013; 73(6):1107-13. PMC: 4033110. DOI: 10.1136/annrheumdis-2012-203075. View

Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6):777-83. DOI: 10.1136/ard.2009.108233. View

10.

Heiberg M, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P . The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008; 59(2):234-40. DOI: 10.1002/art.23333. View

11.

Haroon N, Inman R, Learch T, Weisman M, Lee M, Rahbar M . The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013; 65(10):2645-54. PMC: 3974160. DOI: 10.1002/art.38070. View

12.

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou C . The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010; 70(1):25-31. DOI: 10.1136/ard.2010.133645. View

13.

Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P . Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-700. PMC: 4902107. DOI: 10.1136/gutjnl-2011-301668. View

14.

Vincent F, Morand E, Murphy K, Mackay F, Mariette X, Marcelli C . Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2012; 72(2):165-78. DOI: 10.1136/annrheumdis-2012-202545. View

15.

Chen J, Lin S, Liu C . Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014; (11):CD004800. PMC: 11182569. DOI: 10.1002/14651858.CD004800.pub3. View

16.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

17.

Baraliakos X, Haibel H, Listing J, Sieper J, Braun J . Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2013; 73(4):710-5. DOI: 10.1136/annrheumdis-2012-202698. View

18.

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D . Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015; 373(14):1329-39. DOI: 10.1056/NEJMoa1412679. View

19.

Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, Van den Bosch F . Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014; 73(8):1455-61. DOI: 10.1136/annrheumdis-2014-205178. View

20.

Davis Jr J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D . Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48(11):3230-6. DOI: 10.1002/art.11325. View